페이지 선택

Custom CRISPR sgRNA Lentiviral Vectors & Viruses

Use abm’s All-in-One lentivectors and lentiviruses that express spCas9 or FnCas12a (FnCpf1) along with the sgRNA to simplify the delivery of CRISPR/Cas9 technology right into the target cell. Alternatively, custom sgRNA lentivectors and lentiviruses can be used to deliver sgRNAs into cells that already express the spCas9 nuclease, and thus recruit spCas9 to the target gene (Check out abm’s Cas9-Expressing Stable Cell Lines).

Available Custom CRISPR Vectors and Viruses:

  AAV VECTOR
/VIRUS
LENTIVECTOR
/VIRUS
NON-VIRAL
VECTOR
ADENOVIRUS
sgRNA for spCas9 Available Available Available Available
sgRNA for saCas9 Available
All-in-One with spCas9 Available Available
All-in-One with saCas9 Available
All-in-One with FnCas12a (FnCpf1) Available
  Browse Collection Browse Collection Browse Collection Browse Collection

 

Lentiviruses can infect both dividing and non-dividing cells in vitro and in vivo, and will integrate stably into the host cell genome, ensuring long-term expression of the construct even in cells that are difficult to infect. Lentivectors, on the other hand, allow transient expression and can be diluted out.

We can design sgRNAs for gene knockouts with spCas9 Nuclease, for promoter activation with dCas9-SAM, for promoter repression with dCas9-KRAB, or for transgenic knock-ins of Custom HDR Templates.

Testimonial:

“I have used abm‘s All-in-One lentiviral system to knockout human IL11, which worked really well. Our labmate also ordered the same system from abm to knockout mouse Axl, and she got good results, too. Thus, we want to stick to the same system.”

Dr. Ejung Moon, Stanford University, CRISPR

Additional Resources:

Service Details

 SERVICE NAME VECTOR QUANTITY CAT. NO.
Custom CRISPR sgRNA Lentiviral Vector (for spCas9) – single target pLenti-U6-sgRNA-PGK-Neo 1.0 μg C437
Custom CRISPR sgRNA Lentiviral Vector (for spCas9) – set of three targets pLenti-U6-sgRNA-PGK-Neo 3 x 1.0 μg C441
Custom CRISPR All-in-One Lentiviral Vector (with spCas9) – single target pLenti-U6-sgRNA-SFFV-Cas9-2A-Puro 1.0 μg C438
Custom CRISPR All-in-One Lentiviral Vector (with spCas9) – set of three targets pLenti-U6-sgRNA-SFFV-Cas9-2A-Puro 3 x 1.0 μg C442
Custom CRISPR All-in-One Lentiviral Vector (with FnCas12a / FnCpf1) – Single Target pLenti-U6-sgRNA-EF1a-FnCas12a-2A-GFP 1.0 μg C515
Custom CRISPR All-in-One Lentiviral Vector (with FnCas12a / FnCpf1) – Set of Three Targets pLenti-U6-sgRNA-EF1a-FnCas12a-2A-GFP 3 x 1.0 μg C516

 

PACKAGING SERVICE – STANDARD SIZE TITER CAT. NO.
Custom CRISPR Lentivirus Packaging – single target 300 μl 1.0 μg C437
Custom CRISPR Lentivirus Packaging – three targets, individually packaged 3 x 300 μl 3 x 1.0 μg C441
Custom CRISPR Lentivirus Packaging – three targets, pooled packaging 300 μl 1.0 μg C438

 

Additional Info

 

FAQs

sgRNAs are expressed from the U6 promoter and All-in-One lentivectors and lentiviruses express Cas9 from the SFFV promoter.

The typical lead time is around 1-3 weeks for CRISPR lentivectors and 4-6 weeks for lentiviruses. Please inquire for a more accurate lead time.

Aliquots should be made for the lentivirus and stored at -70 degrees Celsius.

We do the titration after aliquoting and freeze-down. Thus, the titer should be accurate for the customer after they thaw the finished product for the first time.

Our lentivirus expression system is derived from Human HIV-1 Virus. It employs third generation self-inactivating recombinant lentiviral vectors with enhanced biosafety features and minimal relation to wild-type Human HIV-1 Virus.

We use our LV900 series - qPCR Lentivirus Titration(Titer) Kit. This kit quantifies a proprietary region of the lentiviral 5’-LTR.

The maximum insert size is <9 kb between the 5'LTR to 3'LTR.

Citations

01 Kang, Y. J. et al. “Regulation of NKT cell-mediated immune responses to tumours and liver inflammation by mitochondrial PGAM5-Drp1 signalling.” Nat. Commun. (2015) 6:8371 doi: 10.1038/ncomms9371
02 Jiang, G. et al. “Isorhapontigenin (ISO) inhibits invasive bladder cancer (BC) formation in vivo and human BC invasion in vitro by targeting STAT1/FOXO1 Axis.” Cancer Prev Res. Published Online First April 14, 2016.doi: 10.1158/1940-6207.CAPR-15-0338
03 Okugawa, Y. et al. “Clinical significance of SNORA42 as an oncogene and a prognostic biomarker in colorectal cancer.” Gut (2015)doi:10.1136/gutjnl-2015-309359